Clinical Scorecard: FDA Accepts Vamikibart BLA for Uveitic Macular Edema
At a Glance
| Category | Detail |
|---|---|
| Condition | Uveitic macular edema (UME) associated with noninfectious uveitis |
| Key Mechanisms | Vamikibart is an investigational monoclonal antibody designed to inhibit interleukin-6, a proinflammatory cytokine implicated in UME. |
| Target Population | Adults with UME associated with noninfectious uveitis enrolled in the phase 3 MEERKAT and SANDCAT trials. |
| Care Setting | Ophthalmology and retina care; the trials evaluated intravitreal treatment and follow-up through 52 weeks. |
Key Highlights
- The FDA accepted Genentech’s biologics license application for investigational vamikibart; the company said an FDA decision is expected by July 2027.
- MEERKAT and SANDCAT randomized 245 and 256 adults, respectively, to intravitreal vamikibart 0.25 mg, vamikibart 1 mg, or sham at four monthly visits.
- The week 16 primary endpoint results differed between trials: both vamikibart doses were statistically significant versus sham in MEERKAT, while neither met statistical significance in SANDCAT under the reported testing hierarchy.
- Visual acuity and central subfield thickness improvements appeared as early as day 8 and were generally maintained through week 52; visual acuity treatment difference narrowed in the SANDCAT 1-mg group.
- Through week 52, investigators reported relatively low rates of serious ocular adverse events and intraocular inflammation, no ocular occlusive retinal vasculitis, and no new safety signals during as-needed dosing.
Guideline-Based Recommendations
Diagnosis
- The article describes trial eligibility as UME associated with noninfectious uveitis; it does not provide diagnostic criteria.
Management
- Vamikibart remains investigational; the FDA has accepted its BLA, and the article does not provide a treatment recommendation.
- Trial participants received intravitreal vamikibart 0.25 mg, 1 mg, or sham at four monthly visits.
- Rescue treatment could begin at week 4 for worsening vision, macular edema, or uveitis; masked as-needed treatment could begin at week 20 for eligible patients.
Monitoring & Follow-up
- The trials assessed best-corrected visual acuity and central subfield thickness through week 52.
- Safety assessments reported through week 52 included serious ocular adverse events, intraocular inflammation, and ocular occlusive retinal vasculitis.
Risks
- The article notes that corticosteroids, described as the mainstay of treatment, carry risks including elevated intraocular pressure and cataract formation.
- The article reports relatively low rates of serious ocular adverse events and intraocular inflammation with vamikibart through week 52; no ocular occlusive retinal vasculitis or new safety signals during the as-needed phase were reported.
- The week 16 primary endpoint results differed between MEERKAT and SANDCAT, an important consideration in evaluating the evidence.
Patient & Prescribing Data
Adults with UME associated with noninfectious uveitis; 245 participants enrolled in MEERKAT and 256 in SANDCAT.
Participants were randomized equally to intravitreal vamikibart 0.25 mg, vamikibart 1 mg, or sham at four monthly visits. Rescue treatment was permitted from week 4, and masked as-needed treatment from week 20 for eligible patients. Vamikibart is investigational.
Clinical Best Practices
- Interpret the week 16 efficacy findings in light of the differing primary endpoint results in MEERKAT and SANDCAT.
- Consider the reported week 52 visual acuity and central subfield thickness outcomes alongside the trial’s rescue and as-needed treatment provisions.
- Do not treat vamikibart as an approved therapy based on this article; the FDA has accepted the BLA, and a decision was expected by July 2027 according to the company.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







